The abstract is read at the publisher; the summary is JClub's.
Sarcopenia remains without approved pharmacological therapies despite its link to loss of muscle mass, strength, and function and outcomes like falls, fractures, and premature mortality.
- Why it matters: Translation from sarcopenia research to approved drugs has been limited, with barriers including heterogeneity in trial eligibility, follow-up, and outcomes, plus limited regulatory harmonization.
- What they did: A WHO Collaborating Centre working group Perspective synthesizes updated expert views, informed by post-2020 ESCEO trial conduct discussions, covering definitions, regulatory landscape, and pharmacological trial design.
- The result: The Perspective outlines how to align target populations, trial outcomes (including digital health and patient-reported measures), duration, biomarkers, and patient expectations to support future sarcopenia treatment development.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.